NCT04800692 - The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions

Claudication, IntermittentPeripheral Artery DiseasePeripheral Vascular Diseases

Interventions

DRUG

Tetrahydrobiopterin 10 mg/kg

10mg/kg of Tetrahydrobiopterin daily.

DRUG

Tetrahydrobiopterin 20 mg/kg

20mg/kg of Tetrahydrobiopterin daily.

DRUG

L-Ascorbate

3300 mg of l-ascorbate once daily

DRUG

L-Arginine

3400mg of l-arginine once daily

Trial Locations (1)

RECRUITING

UMASS Memorial Healthcare - University Campus, Worcester